|
|
A recent study in Japan indicates that B12 treatment helps in the growth and division of certain immune system cells.11 These pharmacy cells function to prevent drug the immune system from over-reacting info to allergens pharmacy such as animals, mold, dust, and pollen. They are called drug suppressor cells or CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM info is a 21-day treatment of B12 lozenges sucked on twice daily. this medicationTM may help patients with hay fever pharmacy by providing the patient’s suppressor cells with the sustained and elevated blood B12 level they need to grow and divide. It appears drug that by helping the immune system to become what it is genetically capable of becoming, this medicationTM info turns at least some allergic people into non-allergic pharmacy or moderately-allergic people. Studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. It is during this first pass in its native form that drug it is believed to info exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic pharmacy rhinitis (hay fever), drug sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma and allergic rhinitis subjects were treated with B12. Total IgE, info specific IgE and pulmonary pharmacy lung functions were taken at days 45, drug 150 and 180 from baseline. Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites in Riverside County, CA in 1989. Sixteen of the 17 subjects had info lowered IgE levels from Day 0 to pharmacy Day 30.3 In 1992 in El Paso, TX a randomized, double-blind, drug placebo controlled info study of subjects (n=130) with allergic rhinitis in 1992-1993 was conducted. The average IgE level of the placebo treated subjects remained essentially flat, while the average IgE level for active treated subjects was reduced significantly from baseline to Day 30.7 In 1993 in El Paso, TX, valid subjects (n=66) pharmacy returned a second set of symptom drug diaries info which they had completed for days 365 to 395 (the same period, one year after the first set of symptom pharmacy diaries). The active group had mean symptom scores showing statistically significant decreases from 1992 to 1993. The placebo group had increased symptoms drug in 1993. (The relevant pollen counts at the study site in 1993 were much higher than in 1992, leading info to expectation of higher symptoms.)7
|